Sphere Fluidics, a number one supplier of progressive microfluidics-based options for single-cell evaluation and isolation, immediately introduced the appointment of Dale Levitzke as CEO with instant impact, as Dr. Frank F. Craig, present CEO and co-founder, pronounces his retirement.
Dale joins Sphere Fluidics with over 25 years’ expertise within the life science instruments, biopharma, and biotechnology industries, the place he has constructed a robust observe file in efficiently driving innovation, industrial development, and IPO methods. In his position as CEO, Dale will form Sphere Fluidics’ future industrial enterprise and progress the Firm’s continued world growth technique to succeed in new prospects and create worth for shareholders.
All through his profession, Dale has centered on supporting early-stage and VC-backed pioneering instruments firms and steering them in direction of world market success. Earlier than becoming a member of Sphere Fluidics, he was Senior VP of International Gross sales and Help at Vizgen and on this position established a worldwide industrial infrastructure and quickly scaled the Firm’s operations. Previous to this, as VP Worldwide Gross sales and Advertising and marketing at Dropworks Inc., Dale’s contributions have been instrumental in growing an built-in Digital Droplet PCR platform, and his strategic management culminated within the Firm’s acquisition by Bio-Rad for $125 million. He has additionally held key senior positions main industrial growth at NanoString Applied sciences, Illumina Inc., and Helixis Inc. Dale holds a BSc (Hons) in Molecular Biology and Genetics from La Trobe College in Melbourne, Australia.
Dr. Frank F. Craig co-founded Sphere Fluidics, alongside Professor Chris Abell and Professor Wilhelm Huck, earlier than changing into CEO in 2010. On this time, he has led the commercialization of novel merchandise and R&D providers that leverage the Firm’s proprietary picodroplet know-how, and uniquely established it throughout the life science instruments business to deal with a rising portfolio of markets, together with biologics discovery, cell remedy and artificial biology. Sphere Fluidics has a confirmed observe file of over 400 worldwide prospects, together with collaborations with seven of the world’s High 10 pharma firms, over £40 million in funding (from prestigious angel and VC funds), and a portfolio of 135 worldwide patents. The Firm has been nicely positioned to drive this subsequent part of economic improvement ahead.
Sphere Fluidics’ picodroplet know-how and microfluidics platforms are remodeling single cell evaluation and isolation capabilities, bringing new potentialities to biopharmaceutical analysis and improvement. I’d prefer to thank Frank for his dedication to rising an organization that prides itself on delivering high-quality services and products to its prospects. I look ahead to becoming a member of the group to proceed to guide and drive its bold plans for industrial development, worldwide growth, and eventual exit.”
Dale Levitzke, Incoming CEO, Sphere Fluidics
Dr. Frank F. Craig, departing CEO, Sphere Fluidics, commented: “It has been a privilege to function CEO of Sphere Fluidics for over 14 years and I’m delighted to cross the baton onto Dale as he takes over as CEO. His expertise of driving innovation and industrial success will probably be pivotal to advancing Sphere Fluidics’ bold strategic imaginative and prescient and plans for industrial development.”